Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

June 3, 2019

PresentationTivozanib

ASCO 2019: TIVO-3: Subgroup analysis of progression-free survival of tivozanib compared to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)

April 1, 2019

PresentationFiclatuzumab

AACR 2019: CyFi: Results from a phase Ib expansion cohort of ficlatuzumab (Fi) combined with high-dose cytarabine (Cy) in patients with high risk relapsed or refractory acute myeloid leukemia (AML)

February 15, 2019

PresentationTivozanib

ASCO GU 2019: TIVO-3: A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC)

October 22, 2018

PresentationTivozanib

ESMO 2018: TiNivo: Tivozanib Combined With Nivolumab: Safety and Efficacy in Patients With Metastatic Renal Cell Carcinoma (mRCC)

October 21, 2018

PresentationFiclatuzumab

ESMO 2018: Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

March 20, 2018

PublicationTivozanib

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study

Authors: Ana M. Molina, Thomas E. Hutson, Dmitry Nosov, Piotr Tomczak, Oleg Lipatov, Cora N. Sternberg, Robert Motzer, Tim Eisen. Click here for link to article.

« Previous 1 … 5 6 7 8 9 … 15 Next »